Flat 50% Off on All Research Reports! Use code CRISP50 at checkout. Download Now!
Flat 50% Off on All Research Reports! Use code CRISP50 at checkout. Download Now!
In the bustling diplomatic corridors of New Delhi this week, a handshake has changed the future of healthcare, the EU-India healthcare supply chain. The India-EU Free Trade agreement marks the end of a long journey that began in 2007. For nearly two decades, talks often stalled over IPRs and market access. But now, driven by a shared motive and a desire to de-risk from external geopolitical shocks, the two giants have finally aligned.
While the deal covers everything from Automobiles to Expensive Alcohol, our focus here will be on the real jewel that is Healthcare. This pact creates a trade zone of 2 billion people and provides direct access for Indian generics to enter Europe, while bringing high-end European medical innovation to the hospital beds of India.
India’s pharmaceutical prowess is phenomenal, supplying about 20% of the world’s generic drugs. Companies like Sun Pharma, Cipla, Dr Reddy’s are some of the key contributors in the manufacturing of generics.
However, the EU market, with its stringent regulations and varying tariff structures, always remained a tough nut to crack, especially for the small and medium enterprises.
Before the FTA deal, Indian pharmaceutical exports, including formulations and APIs, faced EU tariffs up to 11%. The FTA now effectively slashes this to 0%. So, for Indian Manufacturers, this immediately makes drugs more price competitive against local European players and other global players. And, when it comes to small and medium players which couldn’t absorb the 11% tariff, now can enter the European supply chain easily. Indian exports to the EU currently stands at about $6 billion, and it could very well double by 2032, after this deal.
The most important part of the negotiations was the Intellectual Property. The EU originally had a rule that would prevent generic companies from using existing clinical trial data to gain approval for several years, even after a patent expired.
This deal reaffirms TRIPS aligned protections but excludes Data Exclusivity. This ensures that Indian companies can continue to launch affordable versions of drugs from the moment their patent expires, which will help them maintain the flow of affordable medicine to both Indian and European patients.
While India is a powerhouse in pills, it has historically imported 80% of high-end medical technology, be it MRI machines, CT Scanners, Ultrasound systems and many more, coming from companies like Siemens Healthineers, GE Healthcare and Philips Healthcare to name a few. TheFTA is set to change the math for Indian Hospitals and MedTech startups.
India has agreed to eliminate the custom duties on roughly 90% of medical and surgical equipment coming from the EU. Previously, these duties were as high as 27.5%.
With this, scanners like MRI, CT, PET-CT and robotic systems, largely manufactured in hubs like Germany and Scandinavian countries, will become significantly cheaper in India. And from an average Indian patient perspective, this should eventually translate to lower costs for advanced care and specialised surgeries as hospitals pass on their procurement savings.
On the other side, Indian manufacturers of medical consumables now have duty-free access to Europe. The agreement also sets a roadmap for a Mutual Recognition Agreement. Once it is implemented, an Indian certification for a medical device could be recognized as equivalent to the European “CE” mark.
One of the primary drivers for this deal was the shared vulnerability regarding Active Pharmaceutical Ingredients (APIs). Both India and the EU have been over-dependent on a single source (China) for the raw materials used to make medicines.
The FTA establishes a “Strategic Trade Corridor” for APIs. By lowering tariffs on chemical intermediates and fostering joint R&D, the deal encourages a “China Plus One” strategy. European firms are now incentivized to set up API manufacturing units in Indian hubs like Gujarat, Maharashtra, and Andhra Pradesh, creating a more stable, diversified global supply of medicine.
Despite all the euphoria around the deal, the industry must navigate several hurdles. Regulatory Gap, zero tariffs doesn’t mean zero barriers. Indian firms must still meet the EU’s strict standards. Compliance is expensive and complex paperwork still remains a barrier. While this deal is concluded, it still needs to be translated into 24 languages, signed by all the EU members. So, it will take 12-36 months before the first zero-duty shipments actually cross the borders.
When we see this from a consumer point of view, there a three ways it hits the wallet:
In an era of rising protectionism and trade wards, the EU-India FTA is a declaration of trust and the world’s largest democracies have chosen cooperation. For India, it is a final step in becoming the “Pharmacy of the World” and for the EU it is an insurance policy for healthcare security. As we move towards 2030, this agreement ensures that when the next health crisis hits, the bridge between EU and India will be wide, duty free and open for business.
Want the full institutional breakdown of what this deal means beyond healthcare?
Read the complete CrispIdea newsletter on the India-EU “Mother of All Deals.”
Prem Chulaki is a U.S. Healthcare and Life Sciences equity researcher focused on pharmaceuticals, biotechnology, and medical technology. His work combines scientific and financial diligence—analyzing value chains, pipeline strength, clinical and regulatory risk, and capital allocation—to translate complex healthcare innovation into clear investment insights. He covers sector leaders such as Eli Lilly, Novo Nordisk, Johnson & Johnson, and Zoetis, with a strong interest in GLP-1 therapies, AI-driven drug discovery, and emerging biotech disruption.
No, prices will likely soften by 5-10% starting in 2027 as duty-free stock gradually replaces current inventory.
Most likely, slashing the 27.5% duty on European scanners to 0% reduces hospital setup costs, making advanced diagnostics more accessible.
No, India successfully rejected “Data Exclusivity” rules, ensuring affordable generics can still be launched the moment patents expire.
Following the January 2026 conclusion, the deal is expected to be ratified and implemented by early 2027.
